175 related articles for article (PubMed ID: 32205231)
21. Synergistic Treatment of Tumor by Targeted Biotherapy and Chemotherapy via Site-Specific Anchoring of Aptamers on DNA Nanotubes.
Chen R; Sun P; Chu X; Pu X; Yang Y; Zhang N; Zhao Y
Int J Nanomedicine; 2020; 15():1309-1320. PubMed ID: 32161460
[TBL] [Abstract][Full Text] [Related]
22. Hollow microspheres based on - Folic acid modified - Hydroxypropyl Cellulose and synthetic multi-responsive bio-copolymer for targeted cancer therapy: controlled release of daunorubicin, in vitro and in vivo studies.
Metaxa AF; Efthimiadou EK; Boukos N; Fragogeorgi EA; Loudos G; Kordas G
J Colloid Interface Sci; 2014 Dec; 435():171-81. PubMed ID: 25261841
[TBL] [Abstract][Full Text] [Related]
23. Aptamer-based liposomes improve specific drug loading and release.
Plourde K; Derbali RM; Desrosiers A; Dubath C; Vallée-Bélisle A; Leblond J
J Control Release; 2017 Apr; 251():82-91. PubMed ID: 28238787
[TBL] [Abstract][Full Text] [Related]
24. Self-Assembled DNA-Protein Hybrid Nanospheres: Biocompatible Nano-Drug-Carriers for Targeted Cancer Therapy.
Lee D; Baek S; Kim YY; Bang Y; Jung HN; Im HJ; Song YK
ACS Appl Mater Interfaces; 2022 Aug; 14(33):37493-37503. PubMed ID: 35969502
[TBL] [Abstract][Full Text] [Related]
25. Aptamer CaCO3 nanostructures: a facile, pH-responsive, specific platform for targeted anticancer theranostics.
Zhou C; Chen T; Wu C; Zhu G; Qiu L; Cui C; Hou W; Tan W
Chem Asian J; 2015 Jan; 10(1):166-71. PubMed ID: 25377905
[TBL] [Abstract][Full Text] [Related]
26. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
[TBL] [Abstract][Full Text] [Related]
27. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
28. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
29. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
Luo YL; Shiao YS; Huang YF
ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
[TBL] [Abstract][Full Text] [Related]
30. Spectroscopic, calorimetric and cytotoxicity studies on the combined binding of daunorubicin and acridine orange to a DNA tetrahedron.
Zhang X; Li X; Wang D; Weng T; Wang L; Yuan L; Wang Q; Liu J; Wu Y; Liu M
Spectrochim Acta A Mol Biomol Spectrosc; 2023 Jul; 295():122583. PubMed ID: 36905740
[TBL] [Abstract][Full Text] [Related]
31. Self-Assembled Aptamer-Grafted Hyperbranched Polymer Nanocarrier for Targeted and Photoresponsive Drug Delivery.
Yang L; Sun H; Liu Y; Hou W; Yang Y; Cai R; Cui C; Zhang P; Pan X; Li X; Li L; Sumerlin BS; Tan W
Angew Chem Int Ed Engl; 2018 Dec; 57(52):17048-17052. PubMed ID: 30387923
[TBL] [Abstract][Full Text] [Related]
32. Spectroscopic and cytotoxicity studies on the combined interaction of (-)-epigallocatechin-3-gallate and anthracycline drugs with human serum albumin.
Guo Q; Liu M; Zhao Y; Wu Y; Liu J; Cai C; Shi Y; Han J
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Nov; 222():117213. PubMed ID: 31177010
[TBL] [Abstract][Full Text] [Related]
33. Targeting drug delivery and efficient lysosomal escape for chemo-photodynamic cancer therapy by a peptide/DNA nanocomplex.
Wang Q; He Z; Zhu H; Gao W; Zhang N; Li J; Yan J; He B; Ye X
J Mater Chem B; 2022 Jan; 10(3):438-449. PubMed ID: 34951442
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
35. Aptamer-functionalized gold nanoparticles as photoresponsive nanoplatform for co-drug delivery.
Shiao YS; Chiu HH; Wu PH; Huang YF
ACS Appl Mater Interfaces; 2014 Dec; 6(24):21832-41. PubMed ID: 24949657
[TBL] [Abstract][Full Text] [Related]
36. Anti-Proliferative Effect of Doxorubicin-Loaded AS1411 Aptamer on Colorectal Cancer Cell.
Lohlamoh W; Soontornworajit B; Rotkrua P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2209-219. PubMed ID: 34319045
[TBL] [Abstract][Full Text] [Related]
37. SL2B aptamer and folic acid dual-targeting DNA nanostructures for synergic biological effect with chemotherapy to combat colorectal cancer.
Sun P; Zhang N; Tang Y; Yang Y; Chu X; Zhao Y
Int J Nanomedicine; 2017; 12():2657-2672. PubMed ID: 28435250
[TBL] [Abstract][Full Text] [Related]
38. Functional polymeric DNA nanostructure-decorated cellulose nanocrystals for targeted and stimuli-responsive drug delivery.
Lee Y; Nam K; Kim YM; Yang K; Kim Y; Oh JW; Roh YH
Carbohydr Polym; 2024 Sep; 340():122270. PubMed ID: 38858000
[TBL] [Abstract][Full Text] [Related]
39. Aptamer-targeted DNA nanostructures with doxorubicin to treat protein tyrosine kinase 7-positive tumours.
Liu M; Ma W; Li Q; Zhao D; Shao X; Huang Q; Hao L; Lin Y
Cell Prolif; 2019 Jan; 52(1):e12511. PubMed ID: 30311693
[TBL] [Abstract][Full Text] [Related]
40. Overcoming Drug Resistance in Colon Cancer by Aptamer-Mediated Targeted Co-Delivery of Drug and siRNA Using Grapefruit-Derived Nanovectors.
Yan W; Tao M; Jiang B; Yao M; Jun Y; Dai W; Tang Z; Gao Y; Zhang L; Chen X; Wang QL
Cell Physiol Biochem; 2018; 50(1):79-91. PubMed ID: 30278432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
